AARTI PHARMALABS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 571.4 INR | -1.83% |
|
-7.12% | +13.26% |
| 05-14 | GRIFOLS SHARES DOWN 4.8% AFTER GOTHAM CITY RESEARCH ISSUES REPOR… | RE |
| 05-13 | Aarti Pharmalabs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: March | 2023 |
|---|---|
| Capitalization 1 | 24,999 |
| Enterprise Value (EV) 1 | 26,521 |
| P/E ratio | 12.9 x |
| Yield | 0.73% |
| Capitalization / Revenue | 1,285,151 x |
| EV / Revenue | 1,363,395 x |
| EV / EBITDA | 7,775,278 x |
| EV / FCF | 28,396,972 x |
| FCF Yield | 0% |
| Price to Book | 1.6 x |
| Nbr of stocks (in thousands) | 90,626 |
| Reference price 2 | 275.8 |
| Announcement Date | 22/08/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales | - | - | 11,999 | 19,452 |
| EBITDA | - | - | 2,069 | 3,411 |
| EBIT 1 | -0.1868 | -0.046 | 1,648 | 2,799 |
| Operating Margin | - | - | 13.74% | 14.39% |
| Earnings before Tax (EBT) 1 | -0.1868 | -0.046 | 1,554 | 2,608 |
| Net income 1 | -0.1868 | -0.046 | 1,223 | 1,935 |
| Net margin | - | - | 10.19% | 9.95% |
| EPS 2 | -0.7500 | -0.1838 | 13.49 | 21.35 |
| Free Cash Flow | - | - | -6,998 | 933.9 |
| FCF margin | - | - | -58.32% | 4.8% |
| FCF Conversion (EBITDA) | - | - | - | 27.38% |
| FCF Conversion (Net income) | - | - | - | 48.27% |
| Dividend per Share | - | - | - | 2.000 |
| Announcement Date | 05/02/22 | 05/02/22 | 21/01/23 | 22/08/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | - | - | 2,581 | 1,522 |
| Net Cash position 1 | 2.31 | 2.31 | - | - |
| Leverage (Debt/EBITDA) | - | - | 1.247 x | 0.4462 x |
| Free Cash Flow | - | - | -6,998 | 934 |
| ROE (net income / shareholders' equity) | - | -2.01% | 17.6% | 13.1% |
| ROA (Net income/ Total Assets) | - | -1.15% | 10.1% | 8.19% |
| Assets 1 | - | 4 | 12,106 | 23,620 |
| Book Value Per Share 2 | 9.250 | 9.070 | 153.0 | 172.0 |
| Cash Flow per Share 2 | 10.00 | 10.00 | 9.190 | 2.750 |
| Capex | - | - | 1,412 | 1,197 |
| Capex / Sales | - | - | 11.76% | 6.15% |
| Announcement Date | 05/02/22 | 05/02/22 | 21/01/23 | 22/08/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +13.26% | 635M | |
| +38.59% | 727B | |
| -7.89% | 354B | |
| +15.66% | 328B | |
| +0.24% | 277B | |
| +13.47% | 243B | |
| +7.35% | 205B | |
| -6.42% | 203B | |
| +4.23% | 164B | |
| -1.70% | 164B |
- Stock Market
- Equities
- AARTIPHARM Stock
- Financials Aarti Pharmalabs Limited
